Article
Medicine, General & Internal
Michael A. Puskarich, Nicholas E. Ingraham, Lisa H. Merck, Brian E. Driver, David A. Wacker, Lauren Page Black, Alan E. Jones, Courtney Fletcher, Andrew M. South, Thomas A. Murray, Christopher Lewandowski, Joseph Farhat, Justin L. Benoit, Michelle H. Biros, Kartik Cherabuddi, Jeffrey G. Chipman, Timothy W. Schacker, Faheem W. Guirgis, Helen T. Voelker, Joseph S. Koopmeiners, Christopher J. Tignanelli
Summary: This study found that oral administration of losartan did not improve the PaO2:FiO(2) ratio at 7 days in hospitalized patients with COVID-19 and acute lung injury. The use of losartan also did not improve secondary clinical outcomes and resulted in fewer vasopressor-free days compared to placebo.
Article
Cardiac & Cardiovascular Systems
Zhijie Liu, Ning Bian, Shaorong Wu, Yantao Cao, Yiting Su, Wenying Li, Hairui Li, Xianwu Lan, Can Jiang, Yiming Fan, Jun Guo, Dongdong Chen
Summary: This study aimed to investigate the effects of ACEI/ARB and CCB on the risk of NOAF for hypertensive patients with PPI. The results showed that ACEI/ARB were associated with a lower risk of NOAF compared to CCB, and they also had better improvement in left atrial remodelling.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Shao-Yu Yang, Tao-Min Huang, Tai-Shuan Lai, Nai-Kuan Chou, Chun-Hao Tsao, Yi-Ping Huang, Shuei-Liong Lin, Yung-Ming Chen, Vin-Cent Wu
Summary: The study found that preoperative use of ARBs was associated with a reduced risk of postoperative AKI, especially in high doses, while preoperative use of ACEIs or ARBs was both linked to reduced mortality and did not increase the risk of hyperkalemia.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Medicine, Research & Experimental
Mauro G. Silva, Gerardo R. Corradi, Juan Perez Duhalde, Myriam Nunez, Eliana M. Cela, Daniel H. Gonzales Maglio, Ana Brizzio, Martin R. Salazar, Walter G. Espeche, Mariela M. Gironacci
Summary: This study found that COVID-19 patients have higher levels of ACE2 expression and enzymatic activity in their blood compared to healthy individuals, while levels of AngII and Ang-(1-7) are lower. Even when excluding COVID-19 patients under RAS blockade treatment, ACE2 expression and enzymatic activity remain higher in COVID-19 patients, suggesting the involvement of RAS in COVID-19.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Geriatrics & Gerontology
Maria Cespon-Fernandez, Sergio Raposeiras-Roubin, Emad Abu-Assi, Maria Melendo-Viu, Enrique Garcia-Campo, Andres Iniguez-Romo
Summary: The study found that treatment with ACEi or ARB did not improve outcomes in terms of survival and cardiovascular events in older patients with AF. More randomized clinical trials specifically in the older AF patient population are needed to address this issue conclusively.
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
(2021)
Review
Neurosciences
Naif H. Ali, Hayder M. Al-Kuraishy, Ali I. Al-Gareeb, Ali K. Albuhadily, Rabab S. Hamad, Athanasios Alexiou, Marios Papadakis, Hebatallah M. Saad, Gaber El-Saber Batiha
Summary: This article discusses the pathophysiology of depression and the role of the brain renin-angiotensin system (RAS) in it. It is found that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be effective in the treatment of depression. By regulating serotonin, brain-derived neurotrophic factor, mitochondrial dysfunction, oxidative stress, and neuroinflammation, these drugs can ameliorate the pathophysiology of depression.
CNS NEUROSCIENCE & THERAPEUTICS
(2023)
Article
Multidisciplinary Sciences
Mohitosh Biswas, Most. Sumaiya Khatun Kali
Summary: The use of ACE inhibitors and ARBs in COVID-19 patients was not associated with increased risk of mortality, severe clinical manifestations, or positive SARS-CoV-2 tests compared to patients not taking these medications. The findings suggest that discontinuation of ACE inhibitors or ARBs in treating COVID-19 patients may not be necessary based on current evidence.
SCIENTIFIC REPORTS
(2021)
Review
Medicine, General & Internal
Zhixiang Yu, Dong Zhang, Qiuhe Ji, Fu Yi
Summary: ACEIs/ARBs show good preventive effects on new-onset AF and AF after heart failure. They are particularly effective for preventing secondary AF, especially postoperative AF. However, for patients with hypertension and myocardial infarction, ACEIs/ARBs may not be the best treatment option for preventing AF.
Article
Endocrinology & Metabolism
Kara L. Holloway-Kew, Amelia G. Betson, Kara B. Anderson, Filip Sepetavc, James Gaston, Mark A. Kotowicz, Wan-Hui Liao, Maciej Henneberg, Julie A. Pasco
Summary: Medications used to treat hypertension, especially ACEI and low-dose ARB, are associated with increased fracture risk in men. ACEI use is also associated with higher fracture risk in women.
CALCIFIED TISSUE INTERNATIONAL
(2022)
Review
Biochemistry & Molecular Biology
Pawel Bryniarski, Katarzyna Nazimek, Janusz Marcinkiewicz
Summary: This review article focuses on the immunomodulatory properties of angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) in hypertensive patients. ACEI and ARB can inhibit proinflammatory cytokine secretion, decrease expression of adhesion molecules, and normalize CRP concentration, thus exerting immune regulatory effects. This has significant importance in the treatment of patients with underlying chronic inflammatory responses and may also benefit those with comorbidities like metabolic syndrome, allergies, or autoimmune disorders.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Critical Care Medicine
Genevieve L. Y. Rocheleau, Terry Lee, Yassene Mohammed, David Goodlett, Kevin Burns, Matthew P. Cheng, Karen Tran, David Sweet, John Marshall, Arthur S. Slutsky, Srinivas Murthy, Joel Singer, David M. Patrick, Bin Du, Zhiyong Peng, Todd C. Lee, John H. Boyd, Keith R. Walley, Francois Lamontagne, Robert Fowler, Brent W. Winston, Greg Haljan, Donald C. Vinh, Alison McGeer, David Maslove, Santiago Perez Patrigeon, Puneet Mann, Kathryn Donohoe, Geraldine Hernandez, James A. Russell
Summary: This study examined the effects of angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors in hospitalized COVID-19 patients, focusing on gender differences. The results showed that ARBs were associated with reduced use of ventilation and vasopressors in male patients, but not in female patients. Additionally, sex-based differences in the renin-angiotensin system (RAS) components may contribute to variations in outcomes and responses to ARBs in COVID-19.
CRITICAL CARE MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Jean-Baptiste Guichard, Frederic Anselme, Pascal Defaye, Jacques Mansourati, Dominique Pavin, Jean-Luc Pasquie, Yannick Saludas, Jean-Claude Barthelemy, Frederic Roche, Silvy Laporte, Celine Chapelle, Arnauld Garcin, Cecile Romeyer, Karl Isaaz, Antoine Da Costa
Summary: The study investigated the effect of ramipril compared with placebo on atrial fibrillation occurrence in patients hospitalized for atrial flutter ablation, and found no significant difference between the two groups.
AMERICAN JOURNAL OF CARDIOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Zoya Mohammad, Javaria Ahmad, Ali Sultan, Ashritha Penagaluri, Daniel Morin, Paari Dominic
Summary: Sacubitril/valsartan reduces all-cause mortality in heart failure patients compared to ACEIs/ARBs, but does not decrease the incidence of atrial fibrillation.
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY
(2023)
Review
Cell Biology
Zheng Ma, Mei-Ping Wang, Lian Liu, Shuang Yu, Tian-Ran Wu, Lei Zhao, Ye-Ping Zhang, Hai-Feng Liang, Xin-Chun Yang
Summary: The meta-analysis suggests that the use of ACEI/ARB may increase the risk of COVID-19 infection in the general population, but not in hypertensive individuals. Additionally, ACEI/ARB usage was not associated with adverse outcomes in COVID-19 patients.
Article
Cardiac & Cardiovascular Systems
Hazrije Mustafic, Abdallah Fayssoil, Loic Josseran, Mounir Ouadahi, Lamiae Grimaldi-Bensouda, Olivier Dubourg, Djillali Annane, Nicolas Mansencal
Summary: The use of ACE inhibitors and ARBs in hypertensive patients with COVID-19 showed no significant difference in outcomes compared to those not using these medications. The study concluded that the use of ACE inhibitors and ARBs remains safe and can be continued in hypertensive patients with COVID-19.
AMERICAN JOURNAL OF CARDIOLOGY
(2021)